Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China
SHANGHAI--(BUSINESS WIRE)--Golden Age Health Pte. Ltd. (“GAH”) and Innostellar Biotherapeutics Co., Ltd.…
NKGen Biotech Administers First Dose of Troculeucel to Alzheimers Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy
July 10, 2025 16:30 ET | Source: NKGen Biotech, Inc. SANTA ANA,…
Seegene Launches STAgora, a New Platform for Infectious Disease Analytics
Real-time analytics that empower clinical decision-making and pandemic preparednessGlobal unveiling at ADLM 2025…
Metabolon’s Untargeted Metabolomics Services Used for Breakthrough Study Revealing Powerful Link Between Gut Microbiome, the Metabolome, and Type 2 Diabetes (T2D)
Combining metabolomics, gut microbiome, and clinical data may help prevent and personalize…
GE HealthCare drives innovation in theranostics with latest technological advances
GE HealthCare is helping advance clinical and operational excellence in theranostics and…
Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people…
Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology
CAESAREA, Israel, June 17, 2025 /PRNewswire/ -- A newly published, peer-reviewed study…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
GLOBAL MANCOZEB SUMMIT: ADDRESSING ITS CRUCIAL ROLE IN CROP PROTECTION AHEAD OF EU COURT HEARING
LONDON, June 16, 2025 /PRNewswire/ -- UPL Corporation Ltd. (UPL Corp) - part…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…